CN111094290A - 瑞博西尼的单琥珀酸盐晶型及其制备方法和用途 - Google Patents

瑞博西尼的单琥珀酸盐晶型及其制备方法和用途 Download PDF

Info

Publication number
CN111094290A
CN111094290A CN201880040521.6A CN201880040521A CN111094290A CN 111094290 A CN111094290 A CN 111094290A CN 201880040521 A CN201880040521 A CN 201880040521A CN 111094290 A CN111094290 A CN 111094290A
Authority
CN
China
Prior art keywords
degrees
crystal form
crystal
minus
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880040521.6A
Other languages
English (en)
Other versions
CN111094290B (zh
Inventor
陈敏华
张炎锋
刘远
刘凯
张晓宇
钱佳乐
陈宇浩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Crystal Pharmatech Co Ltd
Original Assignee
Crystal Pharmatech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crystal Pharmatech Co Ltd filed Critical Crystal Pharmatech Co Ltd
Publication of CN111094290A publication Critical patent/CN111094290A/zh
Application granted granted Critical
Publication of CN111094290B publication Critical patent/CN111094290B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

如式(1)所示的化合物瑞博西尼的单琥珀酸盐的晶型X、III和V，以及其制备方法。含有所述晶型的药物组合物。所述晶型在制备周期蛋白依赖性激酶4/6抑制剂和治疗乳腺癌的药物制剂中的用途。
Figure DDA0002323360020000011

Description

PCT国内申请，说明书已公开。

Claims (29)

  1. PCT国内申请，权利要求书已公开。
CN201880040521.6A 2017-07-27 2018-07-23 瑞博西尼的单琥珀酸盐晶型及其制备方法和用途 Active CN111094290B (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN201710622757 2017-07-27
CN2017106227578 2017-07-27
CN201710734913X 2017-08-24
CN201710734913 2017-08-24
CN2017112746543 2017-12-06
CN201711274654 2017-12-06
CN2018101446427 2018-02-12
CN201810144642 2018-02-12
PCT/CN2018/096586 WO2019019959A1 (zh) 2017-07-27 2018-07-23 瑞博西尼的单琥珀酸盐晶型及其制备方法和用途

Publications (2)

Publication Number Publication Date
CN111094290A true CN111094290A (zh) 2020-05-01
CN111094290B CN111094290B (zh) 2022-06-17

Family

ID=65040949

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880040521.6A Active CN111094290B (zh) 2017-07-27 2018-07-23 瑞博西尼的单琥珀酸盐晶型及其制备方法和用途

Country Status (2)

Country Link
CN (1) CN111094290B (zh)
WO (1) WO2019019959A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112034066A (zh) * 2020-09-07 2020-12-04 重庆三圣实业股份有限公司 一种分离测定瑞博西尼及杂质的方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9994579B2 (en) 2014-12-12 2018-06-12 Crystal Pharmatech Co., Ltd. Salt of pyrrolo[2,3-D]pyrimidine compound and novel polymorph of salt
US11414421B2 (en) 2018-01-20 2022-08-16 Natco Pharma Ltd Process for the preparation of ribociclib succinate and its novel crystalline forms thereof
WO2019167068A1 (en) 2018-03-01 2019-09-06 Cipla Limited Novel polymorphs of ribociclib succinate
CA3048036A1 (en) 2018-07-02 2020-01-02 Apotex Inc Novel crystalline form of ribociclib succinate
CN112010857B (zh) * 2019-05-30 2021-11-05 常州制药厂有限公司 一种瑞博西尼单丁二酸盐的晶型

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103201275A (zh) * 2010-11-10 2013-07-10 诺华有限公司 7-环戊基-2-(5-哌嗪-1-基-吡啶-2-基氨基)-7h-吡咯并[2,3-d]嘧啶-6-羧酸二甲酰胺的盐及其制备方法
WO2014097125A1 (en) * 2012-12-20 2014-06-26 Novartis Ag Pharmaceutical combination comprising binimetinib
CN105085533A (zh) * 2014-12-12 2015-11-25 苏州晶云药物科技有限公司 7-环戊基-2-(5-哌嗪-1-基-吡啶-2-基氨基)-7h-吡咯并[2,3-d]嘧啶-6-羧酸二甲酰胺单琥珀酸盐的新晶型

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103201275A (zh) * 2010-11-10 2013-07-10 诺华有限公司 7-环戊基-2-(5-哌嗪-1-基-吡啶-2-基氨基)-7h-吡咯并[2,3-d]嘧啶-6-羧酸二甲酰胺的盐及其制备方法
WO2014097125A1 (en) * 2012-12-20 2014-06-26 Novartis Ag Pharmaceutical combination comprising binimetinib
CN105085533A (zh) * 2014-12-12 2015-11-25 苏州晶云药物科技有限公司 7-环戊基-2-(5-哌嗪-1-基-吡啶-2-基氨基)-7h-吡咯并[2,3-d]嘧啶-6-羧酸二甲酰胺单琥珀酸盐的新晶型
CN105111215A (zh) * 2014-12-12 2015-12-02 苏州晶云药物科技有限公司 一种周期蛋白依赖性激酶抑制剂的晶型及其制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
YI-XIANG ZHANG ET AL.: "Antiproliferative Effects of CDK4/6 Inhibition in CDK4-Amplified Human Liposarcoma In Vitro and In Vivo", 《MOL CANCER THER》 *
吕扬等: "《晶型药物》", 31 October 2009, 人民卫生出版社 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112034066A (zh) * 2020-09-07 2020-12-04 重庆三圣实业股份有限公司 一种分离测定瑞博西尼及杂质的方法
CN112034066B (zh) * 2020-09-07 2022-05-27 重庆三圣实业股份有限公司 一种分离测定瑞博西尼及杂质的方法

Also Published As

Publication number Publication date
CN111094290B (zh) 2022-06-17
WO2019019959A1 (zh) 2019-01-31

Similar Documents

Publication Publication Date Title
CN111094290B (zh) 瑞博西尼的单琥珀酸盐晶型及其制备方法和用途
CN110088088B (zh) {[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸的新晶型及其制备方法
AU2017373239B2 (en) Crystalline forms of a bromodomain and extraterminal protein inhibitor drug, processes for preparation thereof, and use thereof
CN110799501B (zh) 一种食欲素受体拮抗剂的晶型及其制备方法和用途
US20210380596A1 (en) Upadacitinib crystal form and preparation method therefor and use thereof
US11572365B2 (en) Crystal form of upadacitinib, preparation method therefor, and use thereof
US20230039086A1 (en) Bms-986165 crystal form, preparation method therefor and use thereof
WO2020057622A1 (zh) 卡博替尼苹果酸盐晶型及其制备方法和用途
JP2022526822A (ja) ボルシクリブ多形、並びにそれを作製する方法及び使用する方法
US20220002306A1 (en) Crystal form of upadacitinib and preparation method and use thereof
CN111527089B (zh) Acalabrutinib的新晶型及其制备方法和用途
CN110650960B (zh) Acalabrutinib的新晶型及其制备方法和用途
CA3086611C (en) A crystalline form of valbenazine ditosylate, processes for preparation thereof and use thereof
CN112794854A (zh) Ribociclib的半琥珀酸盐晶型CSI及其制备方法和用途
WO2019105359A1 (zh) Acalabrutinib的晶型及其制备方法和用途
AU2021341182A1 (en) Crystal form of resmetirom, preparation method therefor, and use thereof
AU2020378025A1 (en) Crystal form of Aprocitentan, preparation method therefor and use thereof
CN113045554A (zh) 一种非索替尼晶型及其制备方法
US20240287085A1 (en) Crystal form of xevinapant, method for preparing same and use thereof
CN111417624B (zh) Eb-1020的晶型及其制备方法和用途
WO2024120441A1 (zh) 氧异吲哚-5-甲酰胺类化合物或其盐、溶剂合物的结晶形式或无定形形式
CN114344301B (zh) 一种低氧诱导因子脯氨酰羟化酶抑制剂晶型
US20220267326A1 (en) Crystalline form of valbenazine ditosylate, processes for preparation thereof and use thereof
EP4114835A1 (en) Salts and polymorphic forms of 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1h-pyrazol-4-yl)-3h-imidazo[4,5-b]pyridine
CN113677401A (zh) 作为ERK抑制剂的5,6-二氢-4H-噻吩并[2,3-c]吡咯-4-酮化合物的盐

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant